⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of United BioSource Corporation (UBC) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
United BioSource Corporation (UBC)
↗King of Prussia, PA, USA
UBC is a leading global provider of outsourced pharmaceutical and patient support services, specializing in evidence development, patient access, and drug safety solutions for biopharmaceutical sponsors. The company focuses on generating real-world evidence (RWE) throughout a medical product's lifecycle to demonstrate safety, efficacy, and value.
UBC's service portfolio includes observational and registry studies, global pharmacovigilance, REMS program support, and patient access programs. They integrate clinical nursing networks, data analytics, and technology platforms to support biopharma companies in navigating complex regulatory environments and improving patient outcomes.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:-
Industry:CRO
Sub-Industry:Real-World Evidence & Patient Support Services
SIZE & FINANCIALS
Employees:1001-5000
Ownership:private
Status:operating
FUNDING
Investors:Avista Capital Partners
0
CORPORATE STRUCTURE
Subsidiaries:Evidinno Outcomes Research Inc.
Key Partnerships:Osmind (Mental health treatment and research), Thread (SitePlus offering), Datavant (Data connectivity), Seqster
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Bekki Brown - CEO
Annette Stemhagen - Chief Scientific Officer
Karen Turner - Chief Financial Officer
LINKS
Website:ubc.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with United BioSource Corporation (UBC). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.